How Old Do You Have to Be to Take Wegovy? Navigating Age Eligibility and Comprehensive Weight Loss Solutions

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy is FDA-approved only for patients aged 18 and older, making age a basic threshold rather than a comprehensive eligibility measure. However, clinical readiness involves metabolic health history, body composition goals, and individual response patterns—factors that extend far beyond a birth date. PlexusDx helps adults navigate these nuances with compounded GLP-1 medications tailored to genetic and metabolic profiles.

Wegovy Age Requirements and FDA Approval Status

The FDA approved Wegovy (semaglutide injection) for chronic weight management in adults 18 years and older in 2021. This age threshold applies to all patients seeking this branded treatment through traditional pharmacy channels. While 18 marks the legal minimum, prescribers typically evaluate additional factors such as BMI, metabolic history, and comorbid conditions before initiating therapy.

Age requirements exist partly because weight-loss medication trials enrolled primarily adults, leaving limited safety and efficacy data in adolescents. The decision to treat younger patients requires individual clinical judgment and family consultation. Many healthcare providers recommend lifestyle modifications first, then consider pharmacotherapy when other approaches show insufficient progress.

Why Age Eligibility Extends Beyond a Single Number

Reaching 18 years old is necessary but not sufficient for starting GLP-1 therapy. Clinical readiness depends on metabolic maturity, realistic weight-loss expectations, and ability to tolerate medication side effects like nausea and appetite suppression. A 19-year-old with severe obesity and insulin resistance may benefit more from semaglutide than a 45-year-old with mild overweight and no metabolic dysfunction.

Healthcare providers assess body mass index (BMI), diabetes status, cardiovascular risk markers, and medication tolerance before prescribing. This individualized approach prevents unnecessary treatment in patients who might succeed with diet and exercise alone, while ensuring those with metabolic disease receive timely intervention. PlexusDx providers evaluate each patient's complete health picture rather than relying on age as the sole determinant.

Compounded Semaglutide as an Accessible Alternative

PlexusDx offers compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan—a flat monthly price regardless of dose adjustment needs. This medication comes from licensed 503A compounding pharmacies, meeting strict pharmaceutical standards without requiring insurance coverage. Compounded semaglutide provides the same active ingredient as Wegovy but eliminates pharmacy markups and supply-chain delays that make branded options expensive.

Compounded medications allow flexibility in dosing schedules and packaging that branded products may not accommodate. PlexusDx serves all 50 states and accepts HSA/FSA contributions, making treatment financially accessible to adults of any age who meet medical criteria. The personalized approach means your dose may need to go up—your price won't.

Precision Peptide Genetic Testing for Personalized Treatment

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

A patient's genetic profile may indicate stronger response to semaglutide versus tirzepatide, or suggest whether microdose protocols might work better than standard dosing. This precision approach removes guesswork and ensures that treatment aligns with individual biology rather than population averages. Adults of any qualifying age benefit from knowing their genetic predisposition before committing to 6–12 months of therapy.

Clinical Evidence Supporting Adult GLP-1 Weight Loss

Semaglutide trials in adults demonstrate average weight loss of 10–15% body weight over 68 weeks—far exceeding outcomes from diet and exercise alone. These results apply consistently across age groups from young adults to older populations, provided patients maintain medication adherence and lifestyle modifications. Cardiovascular benefits including reduced blood pressure and improved cholesterol profiles extend beyond weight loss itself.

Safety profiles in adults 18–75 years old show similar tolerability, with gastrointestinal side effects declining after 4–8 weeks of therapy. No evidence suggests younger adults tolerate GLP-1 medications differently than older cohorts, though individual variation always exists. PlexusDx providers monitor outcomes through regular check-ins and dose adjustments to maximize efficacy while minimizing discomfort.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Can someone under 18 take Wegovy or semaglutide?

Wegovy is FDA-approved only for adults 18 and older. Compounded semaglutide from PlexusDx follows the same age requirement based on limited clinical trial data in younger populations. Adolescents with severe obesity may discuss off-label options with their prescriber, but this requires specialized pediatric endocrinology evaluation.

What happens to pricing if my semaglutide dose increases over time?

PlexusDx compounded semaglutide injection maintains a flat monthly price at $189/mo month-to-month, or from $149/mo on the 6-month plan regardless of dose escalation. Your dose may need to go up as your body adapts—your price won't. This transparent pricing model removes the cost-anxiety barrier that prevents many patients from reaching their therapeutic dose.

How does PlexusDx semaglutide differ from Wegovy?

Both contain identical semaglutide, but PlexusDx sources from licensed 503A compounding pharmacies rather than pharmaceutical manufacturers. This eliminates brand markups and insurance requirements, delivering the same medication at lower cost to all 50 states. PlexusDx also offers genetic testing and personalized dosing protocols Wegovy doesn't provide.

Is compounded semaglutide from PlexusDx FDA-approved?

Compounded semaglutide is not FDA-approved as a finished drug product, but it's manufactured under 503A compounding pharmacy regulations that require sterility, potency, and quality standards. The active ingredient semaglutide is FDA-approved; compounding allows customization for individual patient needs while maintaining pharmaceutical integrity.

How can genetic testing help me choose between semaglutide and tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Do I need insurance to access PlexusDx semaglutide?

No insurance is required. PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and is HSA/FSA eligible. This pricing structure makes weight-loss therapy accessible to uninsured, underinsured, or self-pay adults across all 50 states without membership fees.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.